Explore

Trendline Trendline
GSK's Bepirovirsen Shows Promising Cure Rates for Chronic Hepatitis B

GSK's Bepirovirsen Shows Promising Cure Rates for Chronic Hepatitis B

GSK's Bepirovirsen Shows Promising Cure Rates for Chronic Hepatitis B
Trendline Trendline
Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval
Trendline Trendline
Ori Biotech and ImmuXell Partner to Advance TCR-T Cell Therapy for Cancer Treatment

Ori Biotech and ImmuXell Partner to Advance TCR-T Cell Therapy for Cancer Treatment

Ori Biotech and ImmuXell Partner to Advance TCR-T Cell Therapy for Cancer Treatment
Trendline Trendline
Molecular Targeting Technologies Unveils Promising Data for GEP-NET Cancer Treatment

Molecular Targeting Technologies Unveils Promising Data for GEP-NET Cancer Treatment

Molecular Targeting Technologies Unveils Promising Data for GEP-NET Cancer Treatment
Trendline Trendline
Turn Therapeutics Publishes Study on GX-03 for Inflammatory Skin Conditions

Turn Therapeutics Publishes Study on GX-03 for Inflammatory Skin Conditions

Turn Therapeutics Publishes Study on GX-03 for Inflammatory Skin Conditions
Trendline Trendline
Ribo Submits Phase 2 Trial for siRNA Therapeutic to EMA

Ribo Submits Phase 2 Trial for siRNA Therapeutic to EMA

Ribo Submits Phase 2 Trial for siRNA Therapeutic to EMA
AP News AP News
Experimental hepatitis B drug might offer 'functional cure' for a subset of patients

Experimental hepatitis B drug might offer 'functional cure' for a subset of patients

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus
Trendline Trendline
Ankyra Therapeutics Presents Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics Presents Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics Presents Novel IL-12 Anchored Immunotherapy at ASCO 2026
Trendline Trendline
Newel Health and Gerresheimer Collaborate to Advance Digital Medicine in Pharma

Newel Health and Gerresheimer Collaborate to Advance Digital Medicine in Pharma

Newel Health and Gerresheimer Collaborate to Advance Digital Medicine in Pharma
Trendline Trendline
Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad
Trendline Trendline
Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed

Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed

Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed
Trendline Trendline
Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors

Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors

Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors